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Background/Aims: The present study aimed to determine the role of cystatin C as a prognostic factor for acute kidney injury and 
survival in cirrhotic patients. Methods: The study investigated 53 liver cirrhosis patients. The renal function was evaluated by 
serum creatinine, serum and urine cystatin C, and 24-hour creatinine clearance on admission. Acute kidney injury was defined as 
a serum creatinine level exceeding the normal range (>1.2 mg/dl) and an increase of at least 50% from the baseline value. 
Multivariate analysis, receiver operating characteristic curve, and survival analysis were used to investigate prognostic factors for 
acute kidney injury and survival. Results: Nine of the 53 cirrhotic patients (17.0%) developed acute kidney injury within 3 months. 
Both serum creatinine and cystatin C were predictive factors for acute kidney injury in univariate analysis, with a diagnostic 
accuracy of 0.735 (95% confidence interval (CI), 0.525-0.945; p=0.028) for serum cystatin C and 0.698 (95% CI, 0.495-0.901, 
p=0.063) for creatinine. In multivariate analysis, only serum cystatin C was an independent risk factor for acute kidney injury. The 
sensitivity and specificity of a serum cystatin C level of >1.23 mg/L to acute kidney injury were 66% and 86%, respectively. Serum 
cystatin C was positively correlated with the Model for End-Stage Liver Disease (MELD) and MELD-Na scores (r=0.346 and 
p=0.011, and r=0.427 and p=0.001, respectively). Comparison of the survival rates over the observation period revealed that a 
serum cystatin C level of >1.23 mg/L was a useful marker for short-term mortality (p<0.001). Conclusions: The accuracy in 
predicting acute kidney injury and short-term mortality was higher for a serum cystatin C level of >1.23 mg/L than for the serum 
creatinine concentration in patients with cirrhosis. (Korean J Hepatol 2010;16:301-307)
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INTRODUCTION
Acute kidney injury is frequently observed in patients with 
liver cirrhosis, and is associated with infection, the use of 
diuretics, reduced effective circulating volume and hepatorenal 
syndrome.
1 In cirrhotic patients, acute kidney injury is 
particularly dangerous because it poses an obstacle to treatment 
and has a direct correlation to mortality. In the case of an 
early-stage decline in renal function, it is possible to achieve 
recovery, or at least delay the deterioration of renal disease, with 
active treatment. However, advanced renal failure results in a very 
high mortality rate.
1,2 Therefore, recognizing renal injury during 
its early stage and beginning aggressive treatment is likely to 
delay the deterioration of renal function and improve prognosis.
The most frequently used clinical markers of renal failure 
include serum creatinine, creatinine clearance, and glomerular 
filtration rate (GFR) measured by dynamic methods.
3,4 Unfor-
tunately, in cirrhotic patients, serum creatinine measurements 
must be interpreted with caution because they can be detected 
within normal ranges by poor dietary intake, loss of muscle mass, 
and renal tubular secretion.
5 Acute kidney injury is not accompanied 
by increase in serum creatinine simultaneously in patients with 
liver cirrhosis and ascites.
6,7 Several early markers of renal 
dysfunction have been proposed, including urine neutrophil 
gelatinase-associated lipocalin, kidney injury molecule-1, and 
interleukin-18.
8-10 However, these markers require complicated test 
procedures, as well as additional research regarding their efficacy.
11
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than creatinine, especially for cirrhotic patients whose muscle 
mass tends to be smaller, because it is produced not just in muscle 
cells but in all nucleated cells.
2,12
Gerbes et al. found that serum cystatin C is more effective for 
detecting kidney injury in advanced cirrhotic patients than serum 
creatinine.
2 There is also a study that reported the efficacy of 
cystatin C as an early biomarker for predicting the occurrence of 
acute kidney injury.
13 Others have proposed the possibility of 
using serum cystatin C in patients with diabetes or heart failure as 
a prognostic factor enabling the early detection of mild renal 
dysfunction and the prediction of mortality.
14,15 However, there 
are only a limited number of studies that examine the possibility 
of using cystatin C as an early marker for predicting acute kidney 
injury and survival in patients with liver cirrhosis.
Therefore, this study observed the changes in renal function in 
patients with liver cirrhosis to evaluate the role of cystatin C as a 
prognostic factor for acute kidney injury. It also examined the 
efficacy of cystatin C measurements in predicting patient survival 
rates.
PATIENTS AND METHODS
1. Patients
This study was conducted by retrospective review on consecutive 
cirrhotic patients who were hospitalized in Department of 
Gastroenterology from June to December 2007. The diagnosis of 
liver cirrhosis was defined as the combination of a physical 
examination showing ascites, an endoscopy showing the existence 
of varices, and an abdominal ultrasonography or computed 
tomography indicating cirrhosis of the liver. At the time of 
admission, patients with acute infection, gastrointestinal bleeding, 
or acute renal failure, as well as those undergoing hemodialysis 
or peritoneal dialysis due to chronic kidney disease, were 
excluded from the study. Follow-ups were performed every three 
months for patients with compensated liver cirrhosis, and every 
1-2 months for those with decompensated liver cirrhosis. This 
study was approved by institutional review board (IRB) in Eulji 
University Hospital.
2. Methods
To evaluate the liver function of cirrhotic patients, a range of 
tests consisting of serum albumin, bilirubin, prothrombin time, 
electrolytes, physical examination, and ultrasonography were 
performed to obtain the Child-Pugh, Model for End-Stage Liver 
Disease (MELD), and MELD-Na scores. The Child-Pugh score 
was assigned as a number between 5 and 15 according to serum 
albumin, bilirubin, prothrombin time extension, ascites, and 
hepatic encephalopathy, then divided into three classes: A (5-6), 
B (7-9), and C (10-15).
16 
The renal function of cirrhotic patients was evaluated by 
testing for serum creatinine, serum and urine cystatin C (Human 
Cystatin C ELISA kits; BioVendor LLC, Candler, NC, USA), 
and 24-hour creatinine clearance. Serum sample was obtained at 
admission time. Urine sample was collected for 24 hours, from 
the second hospital day to the next day. Samples were assayed 
immediately or stored at -20℃. Cystatin C assay employed the 
quantitative sandwich enzyme immunoassay technique. Cystatin 
C kits microplates were precoted with monoclonal antibody 
specific for cystatin C. Dilution buffer was used to dilute samples.
Modification of Diet in Renal Disease (MDRD) equation was 
used to calculate the estimated GFR (e-GFR) using the following 
formula:
e-GFRMDRD (mL/min/1.73m
2)=186×(serum creatinine)-1.154× 
(age)-0.203×(0.742 if female).
The following three formulae were used to calculate the 
estimated GFRs (e-GFRs) using serum cystatin C:
e-GFRHoek (mL/min)=80.35/serum cystatin C-4.32.
17 
e-GFRLansson (mL/min)=99.43×serum cystatin C-1.5837.
18
e-GFRLesley (mL/min)=177.6×serum creatinine-0.65×cystatin 
C-0.57×age-0.20×(0.82 if female).
4 
Acute kidney injury was defined as a serum creatinine level 
was detected over normal range (>1.2 mg/dL) at follow-up 
sample and showed increase of 50% or more from the baseline 
value. Instances suggesting obvious prerenal or intrinsic-renal 
injury caused by dehydration, bleeding, septicemia, drug etc. 
were excluded from analysis.
3. Statistical analysis
All statistical analysis was performed using spss version 12.0 
k (SPSS Inc., Chicago, IL, USA). Data were presented as mean± 
SD or n (%). The chi-square test and Mann-Whitney U-test were 
used to compare variables for renal and hepatic functions 
between different patient groups. The results of comparing the 
correlation between two continuous variables were indicated by 
the correlation coefficient (r) using correlation analysis. The 
reference values for creatinine and serum cystatin C were Mi Yeon Chung, et al. Cystatin C in cirrhosis  303
Table 1. Baseline characteristics in all subjects
n=53
Age (yr)     59±12.79
Male/female 38/15
Serum creatinine (mg/dl)  0.88±0.21
Creatinine clearance (mL/min)  60.53±29.88
e-GFRMDRD (mL/min)  91.69±24.80
Serum cystatin C (mg/L)  1.04±0.32
Urine cystatin C (mg/L)  12.13±11.76
e-GFRHoek (mL/min)  79.26±22.21
e-GFRLarsson (mL/min) 109.26±44.38
e-GFRLesley (mL/min)  85.77±25.17
Data are shown as mean±standard deviation (SD).
yr, years; e-GFR, estimated glomerular filtration rate; MDRD, 
modification of diet in renal disease.
e-GFRMDRD (mL/min/1.73 m
2)=186×(serum creatinine)-1.154×(age)- 
0.203×(0.742 if female).
e-GFRHoek (mL/min)=80.35/serum cystatin C-4.32.
e-GFRLansson (mL/min)=99.43×serum cystatin C-1.5837.
e-GFRLesley (mL/min)=177.6×serum creatinine-0.65×cystatin C-0.57×
age-0.20×(0.82 if female).
Figure 1. ROC curves for serum cystatin C, creatinine, and MELD 
score for predicting the development of acute kidney injury within 
3 months. The AUC values of serum cystatin C, creatinine, and 
MELD score were 0.735, 0.698, and 0.641, respectively.
expressed using a receiver operating characteristic (ROC) curve. 
Reference values were defined the maximum sum of sensitivity 
and specificity with over 0.6 of each value. Cross tabulation 
analysis was used to derive the sensitivity, specificity, positive 
predictive value, and negative predictive value of the reference 
values. Survival analysis was used to compare the cumulative 
incidence of acute kidney injury and mortality rate during the 
observation period. Logistic regression test was performed to 
identify independent factors impacting acute kidney injury and 
mortality. A result was deemed statistically significant when 
p<0.05.
RESULTS 
1. Baseline characteristics
The mean age of 53 cirrhotic patients was 59 years, with 38 
males and 15 female patients. Hepatitis B virus-related hepatitis 
was the most common cause of liver cirrhosis among the patients 
(39.6%), followed by alcoholic hepatitis (30.2%), hepatitis C 
virus-related hepatitis (5.7%), non-alcoholic steatohepatitis (5.7%), 
and unknown causes (18.9%). Ascites was found in 35 patients 
(66%). The average Child-Pugh score was 9.37±2.78, with 
Child-Pugh A consisting of 8 patients (15.1%), Child-Pugh B of 
19 patients (35.8%), and Child-Pugh C of 26 patients (49.1%). 
The MELD score was 14.11±6.22, and the MELD-Na score was 
16.41±7.48. The mean duration of follow-up was 13±8.9 months 
(average±standard deviation). The baseline characteristics were 
shown in Table 1.
2. Serum and urine cystatin C in patients with 
liver cirrhosis
Creatinine clearance and the e-GFRMDRD showed a negative 
correlation with serum cystatin C [r=-0.532 (p<0.001) and 
r=-0.691 (p<0.001), respectively], but had no correlation with 
urine cystatin C and urine cystatin C/urine creatinine ratio 
[r=-0.129 (p=0.2) and r=-0.124 (p=0.3), respectively]. Serum 
cystatin C showed a positive correlation with the MELD and 
MELD-Na scores [r=0.346 (p=0.011) and r=0.427 (p=0.001), 
respectively] but had no correlation with the Child-Pugh score 
(r=0.234; p=0.09). Urine cystatin C was not correlated with 
MELD score (p=0.108), MELD-Na score (p=0.123), or 
Child-Pugh score (p=0.5).
3. Serum cystatin C and acute kidney injury
Nine out of the 53 patients with liver cirrhosis developed acute 
kidney injury during the first three months of follow-up. The 
e-GFRMDRD did not yield noticeable differences between the 
groups with and without acute kidney injury (p=0.18), but the 
formulae utilizing serum cystatin C, i.e., e-GFRHoek and 
GFRLarsson, differed significantly between two groups (p=0.03 
and p=0.03, respectively).
To investigate the efficacy of serum creatinine and serum 
Creatinine
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Table 2. GFR markers and liver function scores according to overall kidney injury
No kidney injury (n=36) Overall kidney injury  (n=17)
*P-value
Serum creatinine (mg/dl) 0.83±0.17 1.00±0.25 0.010
Creatinine clearance (mL/min) 65.39±29.96 50.24±27.80 0.070
e-GFRMDRD (mL/min) 95.27±22.96 84.11±27.50 0.075
Serum cystatin C (mg/L) 0.91±0.20 1.30±0.39 <0.001
e-GFRHoek (mL/min) 86.83±18.08 63.23±22.04 <0.001
e-GFRLarsson (mL/min) 123.58±38.23 78.95±42.05 <0.001
e-GFRLesley (mL/min) 92.01±21.66 72.54±27.55 0.002
Urine cystatin C (mg/L) 11.21±11.46 14.07±12.52 0.312
Child-Pugh score 8.97±2.90 10.23±2.35 0.086
MELD score 13.13±6.00 16.17±1.37 0.084
MELD-Na score 15.11±7.02 19.17±7.88 0.068
Data are shown as mean±SD.
*P<0.05 was evaluated by Mann-Whiney U test.
e-GFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; MELD, model for end-stage liver disease.
e-GFRMDRD (mL/min/1.73 m
2)=186×(serum creatinine)-1.154×(age)-0.203×(0.742 if female).
e-GFRHoek (mL/min)=80.35/serum cystatin C-4.32.
e-GFRLansson (mL/min)=99.43×serum cystatin C-1.5837.
e-GFRLesley (mL/min)=177.6×serum creatinine-0.65×cystatin C-0.57×age-0.20×(0.82 if female).
Table 3. Clinical factors impacting acute kidney injury within 3 months
Exp (B) 95% CI
*P-value
Model 1 Age (yr)  0.98 0.91-1.06 0.725
Serum creatinine (categorical, 0.9 mg/dL)  0.49 0.04-6.01 0.582
Serum cystatin C (categorical, 1.23 mg/L) 23.74   1.72-327.22 0.018
Model 2 Age (yr)  1.00 0.92-1.09 0.850
Serum creatinine (categorical, 0.9 mg/dL)  0.21 0.11-4.07 0.306
Serum cystatin C (categorical, 1.23 mg/L) 33.54   1.25-897.96 0.036
Prothrombin time (INR)  0.25 0.01-6.03 0.396
Albumin (mg/dL)  1.33 0.22-7.91 0.747
Bilirubin (mg/dL)  1.17 0.93-1.48 0.160
Model 3 Age (yr)  0.99 0.92-1.07 0.903
Serum creatinine (categorical, 0.9 mg/dL)  0.49 0.04-6.17 0.585
Serum cystatin C (categorical, 1.23 mg/L) 22.78   1.28-403.31 0.033
MELD-Na  0.95 0.76-1.18 0.652
Child-Pugh score  1.25 0.67-2.34 0.472
*P<0.05, odds ratios with 95% confidence intervals from logistic regression analysis.
yr, years; Exp, exponential; CI, confidence interval; INR, international normalized ratio; MELD, model for end-stage liver disease. 
cystatin C in predicting acute kidney injury, the area under ROC 
curve was calculated (Fig. 1). The results were 0.735 (95% CI, 
0.525-0.945, p=0.028) for serum cystatin C and 0.698 (95% CI, 
0.495-0.901, p=0.063) in creatinine. Using the ROC curve, the 
appropriate cutoff values of serum cystatin C and creatinine for 
predicting acute kidney injury were 1.23 mg/L (sensitivity 0.667, 
1-specificity 0.136) and 0.9 mg/dl (0.85 mg/dl: sensitivity 0.778, 
1-specificity 0.455; 0.95 mg/dl: sensitivity 0.556, 1-specificity 
0.273), respectively. The sensitivity, specificity, positive predictive 
value, and negative predictive value of the cystatin C reference 
value in regard to renal injury occurring within three months 
were found to be 66.7%, 86.4%, 50%, and 92.7%, respectively. 
During the whole observation period, 17 patients (32.1%) were 
developed acute kidney injury. The average initial serum Mi Yeon Chung, et al. Cystatin C in cirrhosis  305
Table 4. Clinical factors impacting acute kidney injury over the observation period
Exp (B) 95% CI
*P-value
Age (yr)  1.01 0.95-1.08 0.659
Serum creatinine (categorical, 0.9 mg/dl)  1.28 0.20-7.94 0.791
Serum cystatin C (categorical, 1.23 mg/L) 12.68   1.44-111.02 0.022
Prothrombin time (INR)  0.36 0.02-4.37 0.419
Albumin (mg/dl)  0.45 0.91-2.23 0.330
Bilirubin (mg/dl)  1.05 0.88-1.24 0.567
*P<0.05, odds ratios with 95% confidence intervals from logistic regression analysis.
yr, years; Exp, exponential; CI, confidence interval; INR, international normalized ratio.
Table 5. GFR markers and liver function scores according to overall mortality
Survival (n=26) Mortality (n=27)
*P-value
Serum creatinine (mg/dl) 0.84±0.19 0.92±0.22 0.152
Creatinine clearance (mL/min) 71.22±28.11 50.24±28.32 0.006
e-GFRMDRD (mL/min) 96.69±26.75 86.88±22.21 0.047
Serum cystatin C (mg/L) 0.91±0.27 1.16±0.33 0.002
e-GFRHoek (mL/min) 88.63±20.61 70.24±20.14 0.002
e-GFRLarsson (mL/min) 128.03±42.90 91.19±38.45 0.002
e-GFRLesley (mL/min) 94.72±24.75 77.14±22.82 0.003
Urine cystatin C (mg/L) 8.05±8.67 16.06±13.1 0.005
Child-Pugh score 8.57±2.88 10.14±2.49 0.031
MELD score 12.00±5.16 16.14±6.56 0.012
MELD-Na score 13.53±6.39 19.18±7.51 0.005
Data are shown as mean±SD.
*P<0.05 was evaluated by Mann-Whiney U test.
e-GFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; MELD, model for end-stage liver disease.
e-GFRMDRD (mL/min/1.73 m
2)=186×(serum creatinine)-1.154×(age)-0.203×(0.742 if female).
e-GFRHoek (mL/min)=80.35/serum cystatin C-4.32.
e-GFRLansson (mL/min)=99.43×serum cystatin C-1.5837.
e-GFRLesley (mL/min)=177.6×serum creatinine-0.65×cystatin C-0.57×age-0.20×(0.82 if female).
creatinine and cystatin C levels were 1.00 mg/dl and 1.30 mg/L 
among patients showing acute kidney injury (Table 2). The area 
under the ROC curve was 0.809 (95% CI, 0.671-0.947, p<0.001) 
in serum cystatin C and 0.719 (95% CI, 0.568-0.870, p=0.011) in 
creatinine.
A multivariate logistic regression analysis was performed to 
discover the factors impacting acute kidney injury during the 
first three months. Among the variables, which included age, 
serum creatinine, and serum cystatin C, only serum cystatin C 
was found to be a significant factor influencing acute kidney 
injury (Model 1). When the prothrombin time, albumin, and 
bilirubin in Model 1 were adjusted, serum cystatin C remained an 
independent prognostic factor (Model 2). Even after correction 
using the MELD-Na and Child-Pugh scores, serum cystatin C 
was found to be an independent risk factor for acute kidney 
injury (Model 3) (Table 3). Serum cystatin C was also the only 
significant factor for predicting acute kidney injury during whole 
observation period, among the variables of age, serum creatinine, 
serum cystatin C, prothrombin time, albumin and bilirubin 
(Table 4).
4. Patients mortality by serum cystatin C and
creatinine levels
During the study period, a total of 27 cirrhotic patients died as 
a result of liver related disease. The death group exhibited higher 
average serum cystatin C (1.16 mg/L vs. 0.91 mg/L, p=0.006) 
and urine cystatin C (16.06 mg/L vs. 8.05 mg/L, p=0.012) 
concentrations compared to the survival group. There was no 306  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
difference between the average serum creatinine concentrations 
of the death group and the survivor group (Table 5). In multivariate 
analysis, serum cystatin C and age showed positive correlation 
with mortality (p=0.029 and p=0.006, respectively). 
When the cumulative mortality rate for the whole observation 
period was determined by using serum cystatin C (>1.23 mg/L)  
serum  andcreatinine (>0.9 mg/dl), a difference was found only 
in the case of serum cystatin C (p<0.001 vs. p=0.140, respectively) 
(Figure 2A, B).
DISCUSSION
Our study showed that serum cystatin C offers a higher level 
of accuracy in predicting acute kidney injury. Serum cystatin C 
also displayed a superior discriminating capacity than serum 
creatinine in predicting short term survival rates.
Renal injury is directly linked to the mortality rate of cirrhotic 
patients. Moreover, patients with advanced liver disease accompanied 
by ascites frequently develop hepatorenal syndrome. Thus, there 
is active ongoing research on the important role played by early 
markers of renal injury in relation to the mortality rate of 
cirrhotic patients.
5 Because serum creatinine levels in cirrhotic 
patients with acute kidney injury usually remain within normal 
range and increase only after the injury has progressed to a 
certain degree, other prognostic factors have been studied as 
potential early markers. However, there are as yet no available 
results involving the clinical use of biomarkers and their efficacy 
in treatment.
11
A recent study reported that serum cystatin C level was useful 
marker for predicting the prognosis of cirrhotic patients with 
ascites.
19 Serum cystatin C was independent factors predicting 
kidney injury and mortality. Our study showed similar outcomes 
to the recent study but with all cirrhotic patients, not only patients 
with ascites. We presented serum cystatin C was independent 
predictor of kidney injury and mortality for itself, comparing 
with urine cystatin C and other formulae using serum cystatin C 
level.
In the present study, both serum creatinine and serum cystatin 
C concentrations, as measured during hospitalization, were 
significantly high for the group exhibiting acute kidney injury 
during the course of the study period. Nonetheless, in the case of 
creatinine, the averages for the group showing a renal event 
within the first three months (1.03 mg/dl) and the group showing 
a renal event within the entire observation period (1.00 mg/dl) 
both fell within the reference range. Therefore, when using 
serum creatinine as an early marker for assessing renal injury in 
cirrhotic patients, a different standard than the clinically used 
reference range is required. Serum cystatin C, along with the 
MELD score and the MELD-Na score, proved to be an independent 
factor relating to the survival rate of cirrhotic patients. Additional 
research is needed to ascertain precisely how cystatin C affects 
patient survival rates. Recent studies have suggested its use as a 
biomarker of chronic inflammation. It has already been reported 
that serum cystatin C is linked to the mortality rate of patients 
with heart failure, regardless of objective renal function,
15 and 
that it yields a higher rate of accuracy than serum creatinine in 
predicting the mortality rate of diabetic patients.
14
The correlation between urinary cystatin C and the GFR has 
been reported by Tian et al.
20 Urinary cystatin C, which is strongly 
basic and has a low molecular weight, is mostly absorbed in the 
proximal tubule after passing through the glomerular basement 
membrane, thus resulting in the correlation noted above.
12 There 
has also been a study proposing a direct relationship with the 
GFR using urinary cystatin C and the urine creatinine ratio,
21 and 
another proposing the increase of initial urinary cystatin C as 
well as urine cystatin C/creatinine ratio as prognostic factors for 
acute kidney injury in post-cardiothoracic surgery patients.
22 
However, in the present study, urinary cystatin C did not 
demonstrated a significant difference in patients displaying acute 
kidney injury. The group that developed renal injuries within the 
first three months had an average urinary cystatin C level of 
11.44 mg/L, while the group that did not show acute kidney 
injury had an average level of 15.50 ng/mL, thus yielding no 
significant difference (p=0.3). Likewise, no difference was observed 
in regard to the assessment of acute kidney injury during the 
whole observation period. Urinary cystatin C may show a 
correlation with acute kidney injury when used in cross-sectional 
GFR calculation or repetitive measurement, but it has no efficacy 
as a singular prognostic factor and requires repeated follow-ups 
or large-scale research.
In cirrhotic patients with serum cystatin C concentrations of 
1.23 mg/L or higher, there is an increased frequency of acute 
kidney injury as well as a higher rate of mortality. Therefore, 
active effort should be devoted to identifying and correcting the 
causative factors for renal dysfunction in such patients. In 
conclusion, serum cystatin C has superior diagnostic value than 
serum creatinine as an early marker for predicting acute kidney 
injury, and is related to mortality in patients with liver cirrhosis.Mi Yeon Chung, et al. Cystatin C in cirrhosis  307
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Figure 2. Cumulative survival rate according to serum cystatin C (A) and creatinine (B) levels. Reference 
values of cystatin C and serum creatinine were 1.23 mg/L and 0.9 mg/dL, respectively.
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